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Abstract
High levels of microparticles (MPs) circulate in the blood of patients with atherosclerotic dis-
eases where they can serve as potential biomarkers of vascular injury and cardiovascular
outcome. We used virtual histology intravascular ultrasound (VH-IVUS) to evaluate the rela-
tionship between the levels of circulating MPs and the coronary plaque composition in
patients with stable angina. We included 35 patients with stable angina (22 men, age 64 ± 9
years) and a de novo target lesion. Preintervention gray-scale and VH-IVUS analysis was
performed across the target lesion. Volumetric analysis was performed over a 10-mm-long
segment centered at the minimum luminal site. Blood samples were obtained from the fem-
oral artery before coronary angioplasty. MPs were measured using a solid-phase capture
assay from a commercial kit. We divided participants into either a low MPs group or high
MPs group based on the median value of MPs. There was no significant difference in base-
line characteristics between the groups. The plaque burden and remodeling index were
similar between the groups. The presence of VH-IVUS-derived thin-cap fibroatheroma was
not different between the groups. The percentage of the necrotic core (NC) was significantly
higher in the high MPs group than in the low MPs group, both in planar (17.0 ± 8.8% vs. 24.1
± 6.9%, p = 0.012) and volumetric analyses (17.0 ± 4.8% vs. 22.1 ± 4.3%, p = 0.002). Circu-
lating MPs were positively correlated with the percentage of the NC area at the minimal
luminal site (r = 0.491, p = 0.003) and the percentage of the NC volume (r = 0.496, p =
0.002). Elevated levels of circulating MPs were associated with the amount of NC in the tar-
get lesion in those with stable angina, suggesting a potential role of circulating MPs as a bio-
marker for detecting unstable plaque in patients with stable angina.
PLOS ONE | DOI:10.1371/journal.pone.0148128 January 26, 2016 1 / 12
OPEN ACCESS
Citation: Min P-K, Cho M, Hong S-Y, Kim J-Y, Choi
E-Y, Yoon Y-W, et al. (2016) Circulating Microparticles
and Coronary Plaque Components Assessed by
Virtual Histology Intravascular Ultrasound of the
Target Lesion in Patients with Stable Angina. PLoS
ONE 11(1): e0148128. doi:10.1371/journal.
pone.0148128
Editor: Vince Grolmusz, Mathematical Institute,
HUNGARY
Received: October 17, 2015
Accepted: January 13, 2016
Published: January 26, 2016
Copyright: © 2016 Min et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This study was supported by grants from
the Korean Society of Lipidology and Atherosclerosis
(Industrial-Educational Cooperation, 2010).
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
Microparticles (MPs) are submicron membrane vesicles that are produced by various vascular
or peripheral blood cells following cellular activation or apoptosis [1]. MPs with complex pro-
coagulant and proinflammatory properties circulate in the blood and can be accumulated in
complicated atherosclerotic plaques [2]. The sequestered MPs within atherosclerotic plaques can
also be exposed to circulation by plaque erosion or rupture [3]. Therefore, it has been reported
that circulating MPs are elevated in patients with acute coronary syndrome (ACS) [4–6].
Recently, it has also been proposed that circulating MPs can be considered a surrogate marker of
vulnerable plaques in the setting of stable angina [7] or asymptomatic carotid artery stenosis [8].
In addition, the level of circulating MPs can be an independent predictor of cardiovascular
events in patients with stable coronary artery disease [9]. Thus, high levels of MPs circulate in
the blood of patients with atherosclerotic diseases where they can serve as a useful biomarker of
vascular injury and a potential predictor of cardiovascular outcome. However, few studies have
evaluated the relationship between circulating MPs and plaque composition by imaging studies
[7]. In this study, we hypothesized that circulating MPs could be a potential biomarker for
detecting unstable coronary plaque. To interrogate this hypothesis, we investigated the relation-
ship between the levels of circulating MPs and the coronary plaque composition determined by
virtual histology intravascular ultrasound (VH-IVUS) in patients with stable angina.
Materials and Methods
Study population
The present study prospectively enrolled 35 patients with stable angina who underwent coro-
nary intervention for a de novo target lesion at the Gangnam Severance Hospital, Yonsei Uni-
versity College of Medicine, Seoul, Korea. Stable angina was defined as no change in the
frequency, duration, or intensity of symptoms within 6 weeks before the intervention. The tar-
get lesion was identified by the combination of exercise electrocardiographic findings, scinti-
graphic reversible defects, and angiographic lesion morphology. In patients who underwent
multivessel intervention, the lesion with the worst diameter stenosis and more complex mor-
phology in the territory of the scintigraphic reversible defects was selected as the target lesion
for VH-IVUS analysis.
Patients who had a history of previous percutaneous coronary intervention (PCI) or coro-
nary artery bypass graft, and those with an ostial lesion, chronic total occlusion, or unsuitable
lesion for IVUS were excluded from this study. Other exclusion criteria were ACS, hemody-
namic instability, chronic kidney disease, apparent infectious disease, chronic inflammatory
disease, and a malignancy.
The study protocol was approved by the Institutional Review Board of the Gangnam Sever-
ance Hospital, Yonsei University of College of Medicine, and written informed consent was
obtained from each patient.
Study procedure and blood sampling
All patients were prescribed chronic aspirin (100 mg/day) and clopidogrel (75 mg/day) ther-
apy for 5 days, or they received a loading dose of oral aspirin (300 mg) and clopidogrel
(300 mg) prior to PCI. A loading dose of intravenous unfractionated heparin (10,000 IU)
was given prior to PCI, and if necessary, a repeat bolus of heparin was administered to main-
tain an activated clotting time of 250–300 s during PCI. Coronary angiography was per-
formed by conventional methods via the femoral artery. Then, balloon angioplasty and stent
implantation were performed according to standard techniques. Blood samples were
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obtained through the femoral sheath prior to PCI to measure the MPs. All blood samples
were drawn into evacuated collection tubes containing sodium citrate (0.109 M). The plasma
supernatant was quickly decanted following a 15 min configuration at 1,500 × g at room
temperature and was then again quickly centrifuged for 12 min at 13,000 × g at room tem-
perature. The platelet-poor plasma containing circulating MPs obtained by double centrifu-
gation was then stored frozen at -80°C for future analysis.
Intravascular ultrasound and virtual histology
Pre-PCI intravascular ultrasound (IVUS) examination was performed on the target lesion
prior to predilation using a 20-MHz 2.9 French IVUS catheter (Eagle Eye, Volcano Therapeu-
tics, Rancho Cordova, CA, USA). After an intracoronary administration of 0.2 mg of nitroglyc-
erin, the IVUS catheter was advanced>10 mm beyond the lesion and then pulled back using a
motorized pullback system to a point>10 mm proximal to the lesion at 0.5 mm/s. During pull-
back, gray-scale IVUS was recorded, and raw radiofrequency data were captured at the top of
the R wave for reconstructing the color-coded map by a VH-IVUS data recorder (Volcano
Therapeutics). Gray-scale quantitative IVUS analyses included the external elastic membrane
(EEM) cross-sectional area (CSA), luminal CSA, plaque and media (P&M, i.e., the EEMminus
the luminal area) CSA, and plaque burden (i.e., the P&M divided by the EEM). The remodeling
index for the PCI target lesion was defined as the ratio of the EEM CSA at the cross-section
with a minimum luminal area to the reference EEM CSA (i.e., the average of the proximal and
distal reference segments). VH-IVUS analysis color-coded tissue as dark green (fibrous tissue
[FT]), light green (fibrofatty [FF]), red (the necrotic core [NC]), or white (dense calcium [DC])
[10]. Planar IVUS analysis was performed at the site of the minimal luminal CSA and at the
site of the largest NC CSA. Volumetric IVUS analysis was performed along a 10-mm segment
centered on the minimal luminal CSA using Simpson’s rule. VH-IVUS analyses were reported
as relative amounts of the plaque area or volume. VH-IVUS-derived thin-cap fibroatheroma
(VH-TCFA) was defined as a necrotic core>10% of the plaque area at the site of the minimal
luminal CSA or the largest NC CSA in at least three consecutive frames without overlying
fibrous tissue in the presence of>40% plaque burden [11].
MP assay
The frozen samples were thawed just prior to analysis. MPs with procoagulant potential were
measured using a solid-phase capture assay from a commercial kit (Zymuphen MP-activity kit;
Hyphen BioMed, France). In brief, MPs were isolated by capture onto immobilized annexin V,
and the amount of captured MPs was determined by a prothrombinase assay using their pro-
coagulant potential. The solid-phase capture assay combined with the prothrombinase assay
provides a functional assessment of the procoagulant potential of isolated circulating MPs,
regardless of the capture ligand [12]. Based on the median value of MPs, we divided our partic-
ipants into either a low MPs group (<the median value of MPs) or a high MPs group (the
median value of MPs).
The cell origins of the MPs were determined by antigenic capture with insolubilized specific
antibodies instead of annexin V using similar solid-phase capture methods [12]. In the present
study, the following biotinylated monoclonal antibodies were used: anti-CD31, anti-CD42b
(Abcam, Cambridge, UK), and anti-CD146 (Millipore, Billerica, MA, USA). Results were
expressed as phosphatidylserine equivalents (PS eq), which were calculated using the standard
calibration curve constructed using liposomes of known concentration. All tests were per-
formed in duplicate.
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Statistical analysis
The normality of data was assessed using the Shapiro-Wilk normality test. Normally distrib-
uted continuous data are expressed as the mean ± standard deviation, while non-normally dis-
tributed continuous variables are presented as median and interquartile range (IQR). For
reasons of uniformity, all gray-scale IVUS parameters are presented as median and IQR. VH-I-
VUS derived plaque components were normally distributed. Normally distributed continuous
variables were analyzed using the Student’s t tests, and non-normally distributed continuous
variables were compared using the Mann-Whitney U-test. Categorical data are presented as
numbers and percentages. Differences in categorical variables were analyzed using the chi-
square test. Correlations between continuous variables were assessed using linear regression
analysis. A two-tailed p value< 0.05 was considered statistically significant. All statistical anal-
yses were performed with PASW statistics, version 18.0 (SPSS, Inc., Chicago, IL, USA).
Results
Thirty-five patients with stable angina (22 men, age 64 ± 9 years) were enrolled in this study.
The enrolled patients were divided into either the low MPs group (n = 17) or high MPs group
(n = 18) based on the median value of MPs (20.0 nM PS eq). In addition to the circulating MPs
captured onto annexin V, the levels of circulating MPs captured with anti-CD31 or anti-
CD42b were also higher in the high MPs group than in the low MPs group (Table 1). The levels
of circulating MPs captured with anti-CD146 had a higher trend in the high MPs group than
in the low MPs group with borderline significance (Table 1).
Baseline clinical and biochemical characteristics were not different between the low MPs
group and high MPs group as listed in Table 2. There was no difference in the pre-procedural
angiographic findings between the two groups (Table 3). The left anterior descending artery
was the most common target lesion location. The quantitative coronary angiographic findings
were similar in both groups. The gray-scale IVUS findings are summarized in Table 4. Planar
IVUS analysis performed at the site of the minimal luminal area and at the site of the largest
NC area, and volumetric IVUS analysis performed along a 10-mm segment centered on the
minimal luminal area were similar between the two groups. There was no significant correla-
tion between the level of MPs and the gray-scale IVUS parameters (data not shown).
The relative plaque composition was compared between the two groups using planar and
volumetric VH-IVUS analyses (Fig 1). The presence of VH-TCFA was not different between
the low MPs group and high MPs group (4/17 [24%] vs. 6/18 [33%], p = 0.711). Although there
was no difference in the percentage of FT, FF, and DC between the two groups at the site of the
minimal luminal area, the percentage of the NC component was higher in the high MPs group
than in the low MPs group (17.0 ± 8.8% vs. 24.1 ± 6.9%, p = 0.012) (Fig 1A). At the site of the
largest NC area, no significant difference was observed in the plaque composition between the
two groups (Fig 1B). In volumetric VH-IVUS analysis of the target lesion, the percentage of the
Table 1. Levels of microparticles captured on annexin V and the different monoclonal antibodies.
Captured antibody Low MPs group (n = 17) High MPs group (n = 18) p value
Annexin V 7.7 (5.5, 9.8) 29.0 (25.9, 39.0) < 0.001
Anti-CD31 2.6 (2.0, 5.0) 7.5 (3.8, 11.0) 0.005
Anti-CD146 1.1 (0.8, 1.7) 1.8 (1.2, 3.0) 0.060
Anti-CD42b 1.5 (0.6, 3.8) 6.1 (3.9, 9.2) < 0.001
Data are presented as median (interquartile range) and expressed as PS eq.
doi:10.1371/journal.pone.0148128.t001
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Table 2. Patients’ baseline characteristics.
Low MPs group (n = 17) High MPs group (n = 18) p value
Age (years) 62 ± 10 67 ± 7 0.209
Male sex 13 (77%) 9 (50%) 0.105
Hypertension 11 (65%) 12 (67%) 0.903
Diabetes mellitus 10 (59%) 8 (44%) 0.395
Current smoker 4 (24%) 5 (28%) 0.774
Ejection fraction (%) 63.8 ± 10.5 62.7 ± 8.0 0.457
Total cholesterol level (mg/dL) 162.8 ± 39.7 154.2 ± 29.9 0.680
Triglyceride level (mg/dL) 178.3 ± 105.6 136.4 ± 74.4 0.162
HDL-cholesterol level (mg/dL) 41.2 ± 10.2 37.9 ± 7.8 0.580
LDL-cholesterol level (mg/dL) 95.5 ± 35.8 92.5 ± 26.4 0.809
White blood cell count (103/μL)a 6.70 (5.22, 8.39) 7.49 (6.01, 8.72) 0.273
Hemoglobin level (g/dL) 13.7 ± 1.7 14.0 ± 1.5 0.729
Platelet count (103/μL) 251.3 ± 59.6 268.6 ± 69.0 0.468
Glucose level (mg/dL)a 108 (99.5, 151.5) 102.5 (91.8, 112.8) 0.163
hs-CRP level (mg/L)a 1.1 (0.4, 3.1) 2.2 (0.8, 5.0) 0.081
Medication
Aspirin 8 (47%) 12 (67%) 0.241
Beta-blocker 4 (24%) 5 (28%) 0.774
ACEI/ARB 9 (53%) 10 (56%) 0.877
Statin 9 (53%) 13 (72%) 0.238
Data are presented as the number (%) of patients or mean ± standard deviation (SD). HDL, high-density lipoprotein; LDL, low-density lipoprotein; hs-CRP,
high-sensitivity C-reactive protein; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
aData are presented as median (interquartile range).
doi:10.1371/journal.pone.0148128.t002
Table 3. Angiographic findings.
Low MPs group (n = 17) High MPs group (n = 18) p value
Target lesion 0.384
LAD 15 (88%) 13 (72%)
LCx 1 (6%) 1 (6%)
RCA 1 (6%) 4 (22%)
Number of diseased vessels 0.305
1 7 (41%) 5 (28%)
2 8 (47%) 7 (39%)
3 2 (12%) 6 (33%)
Reference diameter (mm) 3.2 ± 0.4 3.3 ± 0.4 0.966
MLD (mm) 0.7 ± 0.4 0.6 ± 0.3 0.764
Diameter stenosis (%) 78.6 ± 10.3 80.6 ± 7.6 0.428
Lesion length (mm) 22.5 ± 7.5 25.4 ± 11.0 0.526
Data are presented as the number (%) of patients or mean ± SD. LAD, left anterior descending artery; LCx, left circumﬂex artery; RCA, right coronary
artery; MLD, minimal lumen diameter.
doi:10.1371/journal.pone.0148128.t003
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FT, FF, and DC volume was not different between the two groups. However, the percentage of
the NC volume was significantly higher in the high MPs group than in the low MPs group
(17.0 ± 4.8% vs. 22.1 ± 4.3%, p = 0.002) (Fig 1C). Furthermore, relationships between the levels
of circulating MPs and the percentage of each plaque component were analyzed using planar
VH-IVUS at the site of the minimal luminal area (Fig 2) and volumetric VH-IVUS at the target
lesion volume (Fig 3). The levels of circulating MPs were positively correlated with the percent-
age of the NC area at the minimal luminal site (r = 0.491, p = 0.003) (Fig 2) and the percentage
of the NC volume at the target lesion (r = 0.496, p = 0.002) (Fig 3). When the levels of MPs cap-
tured on different monoclonal antibodies were analyzed, there was no significant correlation
between the MPs levels and the percentage of each plaque component regardless of their cellu-
lar origins (data not shown).
Discussion
In the present study, we demonstrated that the percentage of NC was significantly higher in
patients with high levels of MPs in the setting of stable angina. Moreover, circulating MPs were
positively correlated with the percentage of NC both in planar and volumetric analyses using
an VH-IVUS study. Until now, many efforts have been made to predict high-risk lesions or
vulnerable plaques using plasma biomarkers in patients with stable coronary artery disease.
VH-IVUS has been frequently used to obtain detailed information about the composition and
characteristics of coronary atherosclerotic plaques [13, 14]. Several plasma biomarkers have
been proposed as predictors of ruptured plaque [15] or the plaque composition assessed by
VH-IVUS [16, 17]. Because of their procoagulant and proinflammatory potential, extensive
studies have been performed regarding the role of MPs in atherothrombotic disease such as
ACS [4–6]. It has been proposed that circulating MPs can be considered as a surrogate marker
of vulnerable plaque or global vascular damage [18]. Bernal-Mizrachi et al. [19] were the first
to describe the correlation between circulating MPs and the angiographic lesion morphology
Table 4. Gray-scale IVUS findings.
Low MPs group (n = 17) High MPs group (n = 18) p value
Site of the minimum luminal area
EEM CSA (mm2) 13.3 (10.1, 15.9) 13.1 (11.6, 15.3) 0.782
Lumen CSA (mm2) 2.8 (2.3, 3.9) 2.8 (2.3, 3.3) 0.636
P&M CSA (mm2) 10.2 (7.7, 13.4) 10.7 (9.0, 12.8) 1.000
Plaque burden (%) 78.5 (69.7, 82.4) 78.0 (75.0, 81.5) 0.935
Remodeling index 1.06 (1.00, 1.13) 0.98 (0.90, 1.08) 0.245
Site of the largest necrotic core
EEM CSA (mm2) 14.0 (11.2, 15.9) 13.2 (12.4, 15.2) 0.935
Lumen CSA (mm2) 3.6 (2.8, 5.0) 3.0 (2.8, 3.9) 0.245
P&M CSA (mm2) 9.7 (6.9, 12.9) 10.1 (9.5, 12.4) 0.660
Plaque burden (%) 68.8 (59.3, 80.8) 76.2 (71.8, 78.3) 0.335
Remodeling index 1.09 (1.01, 1.19) 1.06 (0.91, 1.18) 0.405
Target lesion volume (10-mm segment)
Vessel volume (mm3) 126.5 (112.5, 141.0) 128.3 (109.8, 155.8) 0.636
Lumen volume (mm3) 39.5 (17.3, 50.7) 34.6 (26.8, 52.4) 0.909
P&M volume (mm3) 94.5 (66.0, 117.6) 92.7 (76.6, 109.4) 1.000
Plaque burden (%) 73.8 (56.1, 84.0) 72.5 (60.6, 76.9) 0.883
Data are presented as median (interquartile range).
doi:10.1371/journal.pone.0148128.t004
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Fig 1. Comparison of the relative plaque composition between the two groups. The site of the minimum
luminal area (A), site of the largest necrotic core area (B), and target lesion volume of a 10-mm segment
centered on the minimal luminal area (C). Plaque compositions assessed by VH-IVUS were classified into 4
major components: FT, FF, NC, and DC. Data are shown as mean ± 95% confidence interval.
doi:10.1371/journal.pone.0148128.g001
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in patients with ACS. They demonstrated that high circulating levels of endothelial MPs corre-
lated with high-risk angiographic lesions, and suggested that circulating endothelial MPs can
be a useful marker to detect endothelial injury and the risk of ACS [19]. Bernard et al. [7] also
reported that circulating levels of endothelial MPs were significantly higher in the presence of
non-calcified plaques assessed by multidetector computed tomography in patients with type 2
diabetes. However, the relationship between circulating MPs and plaque composition deter-
mined by VH-IVUS remains unknown. We report for the first time a relationship between the
levels of circulating MPs and the coronary plaque components assessed by VH-IVUS in
patients with stable angina.
We demonstrated previously that circulating MPs were elevated locally in culprit coronary
arteries in patients with ST-segment elevation myocardial infarction, and suggested a potential
role of circulating MPs in coronary atherothrombosis in the early period of myocardial infarc-
tion [20]. However, in the current study, the origin of elevated circulating MPs could not be
Fig 2. Correlation between the levels of circulating MPs and relative plaque components assessed by planar VH-IVUS. The following components at
the sites of the minimal luminal area are shown: (A) FT, (B) FF, (C) NC, and (D) DC.
doi:10.1371/journal.pone.0148128.g002
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determined and there was no significant correlation between the levels of MPs captured on dif-
ferent monoclonal antibodies and the percentage of each plaque component. Therefore, the
mechanisms underlying the elevation of circulating MPs and their cellular origin remain to be
elucidated. Considering the pathophysiology of stable angina, the elevated levels of circulating
MPs in unstable coronary plaques with a high NC content can be caused by endothelial injury
and a subsequent inflammatory process. As a surrogate marker of the inflammatory process,
an elevated hs-CRP level was previously reported to be related to the plaque burden in noncul-
prit coronary artery [21] and the amount of NC in the culprit lesion of patients with stable
angina [16]. In our study, the hs-CRP levels showed a positive correlation with the levels of cir-
culating MPs (r = 0.467, p = 0.005), but we could not find any relationship between the hs-CRP
levels and percentages of each plaque component (data not shown). Considering the weak cor-
relation between the hs-CRP level and percentage of plaque components in a previous study
[16], the difference in the number of the study population may explain the discrepancy
Fig 3. Correlation between the levels of circulating MPs and relative plaque components assessed by VH-IVUS analysis. The target lesion volume of
a 10-mm segment centered on the following minimal luminal areas is shown: (A) FT, (B) FF, (C) NC, and (D) DC.
doi:10.1371/journal.pone.0148128.g003
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between the studies. In our study, circulating MPs were a more sensitive marker than the hs-
CRP level for identifying unstable plaques with a high NC content. However, the presence of
VH-TCFA did not differ between the low MPs group and high MPs group. There are several
reasons for the lack of a relationship between the presence of VH-TCFA and the level of MPs
in the present study. First, the study sample was too small to detect a difference in the presence
of VH-TCFA between the two groups. Moreover, the IVUS study was performed only in the
target vessel, and presence of VH-TCFA in non-target vessels could not be evaluated in this
study. Second, a follow-up IVUS was not performed in this study. Therefore, dynamic change
in coronary lesions with high NC contents could not be assessed.
It has been reported that plasma MPs mainly originate from platelets in contrast to the
abundant leukocyte-originating MPs within atherosclerotic plaques [3]. However, Sarlon-Bar-
toli et al. [8] demonstrated that plasma level of leukocyte-derived MPs was significantly higher
in patients with unstable carotid plaque than in those with stable plaque. In addition, plaque
MPs can participate in intercellular communication [22, 23]. Therefore, circulating MPs
derived from other cells beyond platelet or endothelial cells can also participate in the forma-
tion of unstable plaques. However, whether an elevated level of circulating MPs originates
from unstable plaque or whether elevated MPs have an effect on the formation of unstable pla-
que is yet to be determined. Moreover, the role of MPs varies depending on their origin and
composition. Therefore, future work will be required to determine the origin of elevated levels
of MPs and their specific biological role in the formation of unstable plaque.
The present study has some limitations. First, this was a single center study, and the study
sample was relatively small. Therefore, our results need to be validated in larger studies. Sec-
ond, the IVUS study was performed only in the target vessel determined by angiographic anal-
ysis. Therefore, possible influence from unstable plaques in non-target vessels could not be
excluded. Third, the effect of medications, including antiplatelet agents, on the production of
circulating MPs could not be analyzed in this study. Thus, we could not rule out the possible
impact of medications on the level of circulating MPs. Finally, follow-up data were not avail-
able and the prognostic implication of elevated circulating MPs in patients with stable angina
could not be assessed in the current study. Despite these limitations, our study addressed the
possibility of a correlation between the levels of circulating MPs and the plaque composition in
the target lesion of patients with stable angina.
In conclusion, elevated levels of circulating MPs were related to the amount of NC in the
target lesion of stable angina. These findings suggest a potential role of circulating MPs as a
biomarker for detecting unstable plaques in patients with stable angina.
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